摘要
骨质疏松症(osteoporosis,OP)是一种常见的全身性骨病,已成为我国面临的重要公共健康问题。临床实践发现,目前认为的一些原发性OP可能源于钙摄入不足和(或)维生素D缺乏/不足引起的负钙平衡和低血钙所致的甲状旁腺功能增强(亚临床甲旁亢)或亢进,可防可治,故将此类OP称为甲状旁腺功能增强或亢进相关骨质疏松症。我国人群每日钙摄入量普遍不足,维生素D缺乏/不足也是世界性公共健康问题。长期钙摄入不足和(或)维生素D缺乏/不足引起的低血钙和负钙平衡所致甲状旁腺功能增强或亢进相关骨量流失和骨质疏松临床广泛存在,对它的防治可有效防治低骨量和骨质疏松,从而有效防治身高变矮、驼背、腰酸背痛、乏力、骨关节疼痛、骨折、转移性血管钙化和全身钙质沉着症等疾病,提高人民健康水平,助力实现"健康中国2030"的目标。
Osteoporosis(OP)is a common systemic bone disease which has become a serious public health problem in China.In clinical practice,we found that some primary osteoporosis may be due to parathyroid hyperfunction(subclinical hyperparathyroidism)or hyperparathyroidism which is the result of negative calcium balance and hypocalcemia caused by insufficient calcium intake and/or vitamin D deficiency/insufficiency,which is preventable and controllable.Therefore,we call this kind of osteoporosis parathyroid hyperfunction or hyperparathyroidism associated osteoporosis.The daily calcium intake of Chinese people is generally insufficient,and vitamin D deficiency/insufficiency is also a worldwide public health problem.Parathyroid hyperfunction or hyperparathyroidism associated osteopenia and osteoporosis which are results of hypocalcemia and negative calcium balance caused by long-term insufficient calcium intake and/or vitamin D deficiency/insufficiency exist extensively in clinical practice.Its prevention and treatment can effectively prevent and treat osteopenia and osteoporosis,so as to effectively prevent and treat diseases such as short stature,rachiokyphosis,backache,fatigue,bone pain,fracture,metastatic vascular calcification and systemic calcinosis,improve people’s health and help achieve the goal of"Healthy China 2030".
作者
孔令泉
马晨煜
佘睿灵
李凡
吕发金
厉红元
吴凯南
Kong Lingquan;Ma Chenyu;She Ruiling;Li Fan;Lyu Fajin;Li Hongyuan;Wu Kainan(Department of Breast and Thyroid Surgery,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China;Department of Radiology,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
出处
《中华内分泌外科杂志》
CAS
2022年第4期385-390,共6页
Chinese Journal of Endocrine Surgery
